Office-use compounding in New York

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

What was searched to establish the silenceHigh confidence

Education Law Article 137, §§ 6800–6832, with the full section index read; 8 NYCRR Part 63, all seventeen sections fetched and full-text searched, returning zero hits for "office use", "office stock", "503A", "503B", "anticipatory", "USP", "797" or "795"; 8 NYCRR § 29.7; the education department’s advisory notices; and Board of Pharmacy meeting agendas from 2023 to 2026.

Why the silence is not permissionHigh confidence

Three features of § 6810(1) close the escape hatches. The statute reaches "distributed or dispensed", so it covers distribution and not merely dispensing — shipping stock to a clinic is distribution. It applies "to any person", and a licensed prescriber is a person; there is no practitioner carve-out. And the only intermediary exception written into the subsection is pharmacy to pharmacy, itself conditioned on filling a prescription. The legislature wrote one exception and it is not the prescriber’s office.

The criminal hookHigh confidence

Education Law § 6811 makes it a class A misdemeanour for any person to violate any provision of § 6810 (subdivision 19). Subdivision 12 covers selling any drug in violation of the article, and subdivision 9 covers selling any adulterated or misbranded drug.

The verdict in one lineMedium confidence

Silent in form, prohibitive in effect. The silence sits on an express prescription mandate that reaches distribution, an express patient-name label requirement, an unprofessional-conduct rule triggered by the absence of a patient name (8 NYCRR § 29.7(a)(1)), and a class A misdemeanour for violating the mandate.Every citation underneath this is high confidence. The synthesis is a legal reading rather than a holding, and it is the conservative one.

The legislature knew how to authorise office useMedium confidence

It did so, once, and only for outsourcing facilities: § 6831(5)(c)(ix) requires the "Office Use Only" statement on their labels, and § 6831(10) permits administration in a health care setting while barring onward sale or transfer. The omission of any parallel provision for a pharmacy is strong evidence that it is deliberate.The citations are high confidence; the inference from the omission is medium-high.

A second, independent trapMedium confidence

8 NYCRR § 29.7(a)(16) deems a drug adulterated or misbranded if it is not manufactured under the federal current good manufacturing practice regulations at 21 CFR 210 and 211, with a carve-out only for a drug a pharmacy makes "for in-house use". A batch compounded for shipment to a third-party clinic is not in-house use, so on the plain text it must meet those standards or it is adulterated or misbranded — and selling a misbranded drug is the class A misdemeanour above.High confidence on the citation; medium-high on the application, because no guidance construing "in-house use" was found.

The non-patient-specific channel that does exist, and why it does not helpHigh confidence

Education Law § 6807(3) permits dispensing to a registered professional nurse under a non-patient-specific regimen, pursuant to regulations. Those regulations, 8 NYCRR § 64.7, enumerate a closed list of eight subject areas: immunisations, anaphylaxis agents, tuberculosis tests, HIV tests, opioid overdose agents, hepatitis C tests, screening for syphilis, gonorrhoea and chlamydia, and COVID-19 and influenza tests. Separately, 8 NYCRR § 63.13 covers up to a seven-day supply of HIV post-exposure prophylaxis. Nothing on that list is a compounded preparation of the kind clinics source.

The 72-hour prescriber-dispensing cap, and a common misreadingHigh confidence

Education Law § 6807(2)(a) bars a prescriber who does not own or work for a pharmacy from dispensing more than a 72-hour supply, subject to nine exceptions. Exception (7) covers drugs diluted, reconstituted or compounded by a prescriber. It does not exempt drugs compounded by a pharmacy and handed to the prescriber. The two are frequently conflated and the difference is consequential.High confidence on the text; medium-high on the reading.

Registration is the operative gateMedium confidence

Education Law § 6808(1) bars possessing drugs for the purpose of compounding, dispensing, retailing, wholesaling or manufacturing unless registered by the department as a pharmacy, wholesaler, manufacturer or outsourcing facility. Section 6802(21) defines a manufacturer as one who compounds for the purpose of distributing or selling to pharmacies or to other channels of distribution, which pulls in the federal manufacturing standards. There is no New York five-percent wholesale safe harbour — the phrase returns zero hits in § 6808.High confidence on the citations and on the absence of a five-percent safe harbour; medium on the characterisation, because no departmental guidance applying the manufacturer definition to a compounding pharmacy was found.

Out-of-state pharmacies get no home-state shelterHigh confidence

Education Law § 6808-b(1)–(2) requires registration of any out-of-state pharmacy, manufacturer, wholesaler or outsourcing facility that ships, mails or delivers prescription drugs or devices to establishments, authorized prescribers or patients in New York. And 8 NYCRR § 63.8(b)(5)(vi) binds a registered nonresident establishment to Education Law §§ 6810 and 6811 for anything delivered into the state. The prescription requirement and the misdemeanour follow the shipment across the state line by express regulatory adoption.

No USP adoptionHigh confidence

New York has not adopted USP 795 or USP 797 by regulation — zero occurrences across Part 63 and § 29.7.High for the text that was fetched; see the currency caveat below.

Recordkeeping and reportingHigh confidence

Five years (Educ. Law § 6810(5); 8 NYCRR §§ 63.6(a)(7)(ii)(c), 63.6(c)(6), 63.6(c)(8)(ii), 63.8(b)(7)(ii)). Reporting duties attach to outsourcing facilities only: a semi-annual product report to the Board, adverse event reports under Educ. Law § 6831(13), and annual inspection results. Note that the isolated-transaction exception at 8 NYCRR § 63.8(e), for up to 600 prescriptions a year, does not apply to nonresident outsourcing facilities.

Last changeHigh confidence

Statutes verified current to January 1, 2026 via a second publisher, with no substantive change to the office-use landscape. No 2025 or 2026 regulatory amendment is recorded for §§ 63.6, 63.8, 29.7 or 64.7. The Board’s USP committee is an active standing agenda item into mid-2026.The forward risk in New York is that the Board adds compounding standards, not that it opens an office-use channel. That inference is medium confidence.

New York at a glance

Receiving 503B office stock in New York

New York registers the facility with the Education Department rather than a pharmacy board, and there is no volume below which a facility may skip it. New York is also the state where the 503B route is cleaner as a matter of law rather than marketing: 8 NYCRR 29.7(a)(16) deems a drug misbranded unless it is manufactured in accordance with the good manufacturing practices in 21 CFR Parts 210 and 211, and an outsourcing facility is required to operate under those parts — so it satisfies the rule on its face rather than by reaching for an exception.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What New York asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

A nonresident establishment registration with the State Education Department. Education Law § 6808-b(1) defines the term to include an "outsourcing facility located outside of the state that ships, mails or delivers prescription drugs or devices to other establishments, authorized prescribers and/or patients residing in this state" — prescribers are named expressly, and have been since 2014. The fee is $825 initial and $520 triennial.Two traps. 8 NYCRR 63.8(e) states that "the isolated transactions exception shall not apply to nonresident outsourcing facilities", and no volume threshold for them exists at all, so a single shipment triggers registration. And the widely quoted $345 / $260 figures are the nonresident PHARMACY fee under § 6808-b(4)(g), not this one.

Does your practice need a permit?High confidence

None. Education Law § 6808(1) requires registration to possess drugs "for the purpose of compounding, dispensing, retailing, wholesaling, or manufacturing" — administering is absent from that list. Section 6831(10) supplies the affirmative half: "This does not prohibit the administration of a drug in a health care setting."This rests on statutory text and an inference from a negative. No NYSED declaratory ruling, board opinion or FAQ saying in terms that an administration-only practice needs no registration was located.

Administer vs dispenseHigh confidence

Prescriber dispensing is capped at a 72-hour supply under Education Law § 6807(2)(a). Administration in a health care setting is expressly preserved by § 6831(10), and § 6831(5)(c)(ix) mandates an "Office Use Only" label on outsourcing-facility product — New York statute presupposes that lawful office-stock supply exists.

Scheduled (controlled) stockMedium confidence

Different, and not fully researched. Public Health Law § 3304(1) lists "administer" and "possess" where § 6808(1) does not, and § 3343(2) requires practitioners to keep records of all controlled substances received and dispensed under 10 NYCRR Part 80 — a Part we did not retrieve. Treat any specific New York controlled-substance office-stock recordkeeping claim, including one from a supplier, as unverified.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• We could not run a bill-level search of the 2025-2026 legislative session: the open-legislation API returned an authorisation error and both chambers' search tools are script-driven. Statutory text here is verified current to January 1, 2026, and anything enacted after that date is not verified on this page.
• The State Register notice site returned an access error, so regulatory currency rests on a secondary source’s amendment histories with no stated "current through" date. Treat the regulatory text as medium-high on currency rather than high, and verify §§ 63.6, 63.8, 63.12, 63.13, 29.7 and 64.7 against the official compilation before relying on them.
• Departmental newsletters returned an access error, and we found no guidance addressing med spas anywhere.
• Controlled-substance office-stock mechanics are not verified here. That gap bears directly on any scheduled hormone preparation, and it remains an open question on this page.
• Education Law § 6819, which authorises the commissioner to promulgate exceptions, is unfetched. Whether any relevant exception has been promulgated is unverified, and closing that gap is the first thing to do before relying on this page.
• Beyond the primary sources cited here, we have not surveyed board newsletters, declaratory statements, enforcement actions, disciplinary orders or coverage of pending bills. Read nothing into that silence — it means we have not looked, not that nothing is there.